Cantor Fitzgerald analyst Louise Chen initiated coverage of Zai Lab with an Overweight rating and $70 price target. The peak sales potential of Zai Lab’s products and pipeline are under-appreciated and the firm expects upward earnings estimate revisions to move the stock higher, the analyst tells investors in a research note, adding that this could be driven by the better-than-expected sales for marketed drugs, data readouts/pipeline advancements, and free call options on three assets with blockbuster potential.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on ZLAB:
- Zai Lab initiated with an Overweight at Cantor Fitzgerald
- Zai Lab Announces Second Quarter 2023 Financial Results and Corporate Updates
- Zai Lab reports Q2 EPS (13c), consensus (79c)
- ZLAB Earnings this Week: How Will it Perform?
- Zai Lab to Announce Second Quarter 2023 Financial Results and Corporate Updates on August 7, 2023